Greenwich LifeSciences, Inc. (GLSI)
NASDAQ: GLSI · Real-Time Price · USD
24.65
+0.36 (1.48%)
Jun 3, 2026, 12:03 PM EDT - Market open
Greenwich LifeSciences Market Cap
Greenwich LifeSciences has a market cap or net worth of $361.82 million as of June 3, 2026. Its market cap has increased by 179.86% in one year.
Market Cap
361.82M
Enterprise Value
350.36M
1-Year Change
179.86%
Ranking
Category
Stock Price
$24.65
Market Cap Chart
Since the IPO on September 25, 2020, Greenwich LifeSciences's market cap has increased from $68.69M to $361.82M, an increase of 426.76%. That is a compound annual growth rate of 33.93%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 2, 2026 | 356.53M | 22.48% |
| Dec 31, 2025 | 291.08M | 97.19% |
| Dec 31, 2024 | 147.61M | 9.21% |
| Dec 29, 2023 | 135.16M | -30.79% |
| Dec 30, 2022 | 195.29M | -38.84% |
| Dec 31, 2021 | 319.29M | -31.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Vanda Pharmaceuticals | 368.63M |
| Benitec Biopharma | 363.47M |
| Puma Biotechnology | 355.28M |
| Lexeo Therapeutics | 354.13M |
| Enanta Pharmaceuticals | 348.94M |
| Lyell Immunopharma | 347.44M |
| Fennec Pharmaceuticals | 346.68M |
| Prelude Therapeutics | 346.13M |